Integrins: Molecular targets in cancer therapy

被引：148

作者：

Tucker G.C. ^{[1
]}

机构：

[1] Institut de Recherches Servier, Cancer Drug Discovery, 78290 Croissy sur Seine

来源：

Current Oncology Reports | 2006年 / 8卷 / 2期

关键词：

Integrin; Acute Myeloid Leukemia; Progressive Multifocal Leukoencephalopathy; Abciximab; Natalizumab;

D O I：

10.1007/s11912-006-0043-3

中图分类号：

学科分类号：

摘要：

Integrins are cell surface adhesion molecules coupling the extracellular environment to the cytoskeleton as well as receptors for transmitting signals important for cell migration, invasion, proliferation and survival. At least six integrin inhibitors are being evaluated in clinical trials for cancer. Currently, patients with melanoma and glioblastoma multiforme benefit from Vitaxin (MedImmune, Gaithersburg, MD) or cilengitide treatment, respectively. Many phase II trials are being or have been conducted with these two compounds (the most advanced). Surprisingly, despite the broad theoretical impact of such molecules on integrin function, and thus on pathology, the clear identification of discrete clinical niches for their use remains to be defined. Possible reasons for this are discussed in this review. The parallel development of integrin antagonists as imaging tools for patient selection may accelerate the discovery of new avenues for their use. © 2006 by Current Science Inc.

引用

页码：96 / 103

页数：7

共 55 条

[1] Hynes R.O., Integrins: Bidirectional, allosteric signaling machines, Cell, 110, pp. 673-687, (2002)
[2] Haubner R., Finsinger D., Kessler H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibiitors of the alphavbeta3 integrin for a new cancer therapy, Angew Chem Int Ed Engl, 36, pp. 1374-1389, (1997)
[3] Ginsberg M.H., Partridge A., Shattil S.J., Integrin regulation, Curr Opin Cell Biol, 17, pp. 509-516, (2005)
[4] Stupack D.G., Integrins as a distinct subtype of dependence receptors, Cell Death Differ, 12, pp. 1021-1030, (2005)
[5] Hood J.D., Cheresh D.A., Role of integrins in cell invasion and migration, Nature Rev Cancer, 2, pp. 91-100, (2002)
[6] Felding-Habermann B., Integrin adhesion receptors in tumor metastasis, Clin Exp Met, 20, pp. 203-213, (2003)
[7] Jin H., Varner J., Integrins: Roles in cancer development and as treatment targets, Br J Cancer, 90, pp. 561-565, (2004)
[8] Reynolds L.E., Wyder L., Lively J.C., Et al., Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins, Nat Med, 8, pp. 27-34, (2002)
[9] Hodivala-Dilke K.M., Reynolds A.R., Reynolds L.E., Integrins in angiogenesis: Multitalented molecules in a balancing act, Cell Tissue Res, 314, pp. 131-144, (2003)
[10] Castel S., Pagan R., Mitjans F., Et al., RGD peptides and monoclonal antibodies, antagonists of alphav-integrin, enter the cells by independent endocytic pathways, Lab Invest, 81, pp. 1615-1626, (2001)

← 1 2 3 4 5 6 →